Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SciClone Pharmaceuticals has said it plans to initiate a phase II dose-ranging study of its proprietary infectious compound after reviewing positive research on the drug.
Subscribe to our email newsletter
The compound, SCV-07, has potential ability to fight viral infectious diseases and has demonstrated immunomodulatory activity by increasing T-cell differentiation and function, biological processes that are necessary for the body to fight off infection.
Recently, SCV-07 was shown to interact with Toll-like Receptors (TLRs) of the innate immune system. Data from a phase I trial showed that SCV-07 taken orally was safe and led to circulating plasma concentrations similar to those obtained in previous phase I studies using a subcutaneous injection of SCV-07.
The phase II trial will be initiated in the second quarter of 2007. The company is also evaluating this compound in a variety of animal models of disease and will report the results of these studies in the third quarter.
SciClone acquired exclusive worldwide rights, outside of Russia, to SCV-07 from biotechnology company Verta.